WHAT IS CLAIMED IS:

1. Use of an antibody that binds to colony stimulating factor 1 receptor (CSF-1R) in the manufacture of a medicament for the treatment of chronic graft-versus-host disease (cGVHD)-related bronchiolitis obliterans syndrome in a human subject. .

2. The use of claim 1, wherein the antibody comprises a variable heavy (VH) domain comprising VH complementarity determining region (CDR)1 (VHCDR1), VH CDR2, and VH CDR3, wherein:
the VH CDR1 comprises the amino acid sequence GFSLTTYGMGVG (SEQ ID NO:6);
the VH CDR2 comprises the amino acid sequence NIWWDDDKYYNPSLKN (SEQ ID NO:7); and
the VH CDR3 comprises the amino acid sequence IGPIKYPTAPYRYFDF (SEQ ID NO:8); and
wherein the antibody comprises a variable light (VL) domain comprising VL CDR1, VL CDR2, and VL CDR3, wherein:
the VL CDR1 comprises the amino acid sequence LASEDIYDNLA (SEQ ID NO:9);
the VL CDR2 comprises the amino acid sequence YASSLQD (SEQ ID NO:10); and
the VL CDR3 comprises the amino acid sequence LQDSEYPWT (SEQ ID NO:11).

3. The use of claim 2, wherein the VH domain comprises the amino acid sequence EVTLKESGPALVKPTQTLTLTCTFSGFSLTTYGMGVGWIRQPPGKALEWLANIWWD DDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIGPIKYPTAPYRYF DFWGQGTMVTVS (SEQ ID NO:4) and the VL domain comprises the amino acid sequence DIQMTQSPSSLSASVGDRVTITCLASEDIYDNLAWYQQKPGKAPKLLIYYASSLQDG VPSRFSGSGSGTDYTLTISSLQPEDFATYYCLQDSEYPWTFGGGTKVEIK (SEQ ID NO:5).

4. The use of claim 1, wherein the antibody comprises a heavy chain and a light chain, and wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO:12 and the light chain comprises the amino acid sequence set forth in SEQ ID NO:3.

5. The use of claim 1, wherein the antibody is emactuzumab, AMG820, cabiralizumab, IMC-CS4, or DCB-AB21.

6. The use of any one of claims 1 to 5, wherein the human subject has received at least two previous cGVHD treatments.

7. The use of any one of claims 1 to 5, wherein the human subject has received at least three previous cGVHD treatments.

8. The use of any one of claims 1 to 5, wherein the human subject has received at least four previous cGVHD treatments.

9. The use of any one of claims 1 to 5, wherein the human subject has received at least five previous cGVHD treatments.

10. The use of any one of claims 1 to 5, wherein the human subject has received at least six previous cGVHD treatments.

11. The use of any one of the preceding claims, wherein the antibody is to be administered intravenously.

12. The use of any one of claim 1 to 11, wherein the antibody is to be administered intravenously at a dose of 0.3 mg/kg.

13. The use of any one of claims 1 to 11, wherein the antibody is to be administered intravenously at a dose of 1 mg/kg.

14. The use of any one of claims 1 to 11, wherein the antibody is to be administered intravenously at a dose of 3 mg/kg.

15. The use of any one of claims 1 to 11, wherein the antibody is to be administered intravenously once every two weeks at a dose of 0.3 mg/kg.

16. The use of any one of claims 1 to 11, wherein the antibody is to be administered intravenously once every two weeks at a dose of 1 mg/kg.

17. The use of any one of claims 1 to 11, wherein the antibody is to be administered intravenously once every four weeks at a dose of 3 mg/kg.

18. The use of any one of claims 1 to 11, wherein the antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO:12 and the light chain comprises the amino acid sequence set forth in SEQ ID NO:3, and wherein the antibody is to be administered intravenously at a dose of 0.3 mg/kg.

19. The use of any one of claims 1 to 11, wherein the antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO:12 and the light chain comprises the amino acid sequence set forth in SEQ ID NO:3, and wherein the antibody is to be administered intravenously at a dose of 1 mg/kg.

20. The use of any one of claims 1 to 11, wherein the antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO:12 and the light chain comprises the amino acid sequence set forth in SEQ ID NO:3, and wherein the antibody is to be administered intravenously at a dose of 3 mg/kg.

21. The use of any one of claims 1 to 11, wherein the antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO:12 and the light chain comprises the amino acid sequence set forth in SEQ ID NO:3, and wherein the antibody is to be administered intravenously once every two weeks at a dose of 0.3 mg/kg.

22. The use of any one of claims 1 to 11, wherein the antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO:12 and the light chain comprises the amino acid sequence set forth in SEQ ID NO:3, and wherein the antibody is to be administered intravenously once every two weeks at a dose of 1 mg/kg.

23. The use of any one of claims 1 to 11, wherein the antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO:12 and the light chain comprises the amino acid sequence set forth in SEQ ID

NO:3, and wherein the antibody is to be administered intravenously once every four weeks at a dose of 3 mg/kg.

24. The use of any one of claims 1 to 23, wherein the cGVHD is advanced cGVHD.